News & Updates
Showing Gastroenterology articles
Showing
Show Multimedia Only

OLE data FORTIFY risankizumab role in Crohn’s disease
13 Dec 2024
byAudrey Abella
Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
13 Dec 2024








